Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07022977 · ClinicalTrials.gov registry record · Phase 1
A Study of MET233 in Individuals With Obesity or Overweight
A Phase 1 study of Obesity and Overweight, sponsored by Metsera, a wholly owned subsidiary of Pfizer.
- Active
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT07022977: Active Phase 1 study of Obesity and Overweight, sponsored by Metsera, a wholly owned subsidiary of Pfizer.
NCT07022977 is a Phase 1 study of Obesity and Overweight that is active but no longer recruiting, run by Metsera, a wholly owned subsidiary of Pfizer. The registered enrollment target is 120 participants, below the 461-participant average among 27 other Obesity and Overweight trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07022977, a Phase 1 study of Obesity and Overweight, is active but no longer recruiting, sponsored by Metsera, a wholly owned subsidiary of Pfizer.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of once-weekly subcutaneous injections of MET233 in otherwise healthy adults with overweight or obesity. The trial will be conducted in three parts. Part A consists of single ascending dose (SAD) cohorts of MET233 or placebo. Part B consists of multiple ascending dose (MAD) cohorts, with participants treated with five once-weekly doses of MET233 or placebo. In Part C, participants will receive once-weekly doses of MET233 or placebo for 12 weeks, followed by a single higher, potential monthly dose.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL MET233
Study Locations (1)
California
- MET233 Research Site 001 - Cypress
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2024-11-20 |
| Est. Completion | 2026-04-15 |
| Phase | Phase 1 |
What the registry record for NCT07022977 still lists
NCT07022977 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 461-participant average among 27 other Obesity and Overweight trials with a reported enrollment target (74% lower).
The record links to 1 condition, with Obesity and Overweight appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07022977 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT07022977 about?
NCT07022977 is a clinical study titled "A Study of MET233 in Individuals With Obesity or Overweight". The goal of this clinical trial is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of once-weekly subcutaneous injections of MET233 in otherwise healthy adults with overweight or obesity. The trial will be conducted in three parts. Part A consists of single ascending dose...
What is the current status of trial NCT07022977?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2024-11-20. Estimated completion is 2026-04-15.
What conditions does trial NCT07022977 study?
This clinical trial studies the following conditions: Obesity and Overweight.
What interventions are being tested in trial NCT07022977?
The interventions under investigation include: Placebo (BIOLOGICAL), MET233 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07022977?
This trial is sponsored by Metsera, a wholly owned subsidiary of Pfizer, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07022977 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity and Overweight
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07022977's enrollment target sits among peer trials
120 9th of 27 higher than 19 of 27 other Obesity and Overweight trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity and Overweight trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 1 Study of WVE-007 in Adults Living With Overweight or Obesity
RECRUITING · Phase 1
-
Metabolic Health, Bones and Nuts During Weight Loss in Adults
RECRUITING · NA
-
FAMily-centered WEight Loss for Black Adults (FAM WEL B-ing)
RECRUITING · NA
-
Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity
RECRUITING · Phase 3
-
New Mechanisms of Obesity
RECRUITING · NA
-
Weight Management Intervention in College: A Pilot
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI